US WorldMeds Receives the Sarcoma Foundation of America's 2026 Vision of Hope Award

Company recognized for advancing treatment options in sarcoma and for embedding the patient advocacy perspective into its development and regulatory work

LOUISVILLE, Ky., Oct. 9, 2026 /PRNewswire/ -- US WorldMeds announced that it received the 2026 Vision of Hope Award from the Sarcoma Foundation of America (SFA). The award was presented on October 6, 2026, at the Stand Up to Sarcoma Gala in New York City, with representatives from across the SFA community in attendance.

SFA previously presented the award to Adaptimmune in 2022 for its work developing TECELRA® (afamitresgene autoleucel). US WorldMeds acquired TECELRA in 2025 and has continued that mission by working to secure the product's full FDA approval, while continuing to pursue new therapeutic opportunities for people living with sarcoma.

In selecting US WorldMeds, SFA cited not only the company's commitment to bringing new treatment options to people living with sarcoma, but also the way the organization has engaged with the community throughout that journey, actively valuing and incorporating the patient advocacy perspective into its regulatory and development efforts. SFA characterized this approach as a model for how industry and advocacy organizations can work together to advance care and improve outcomes.

"Sarcoma remains an underfunded and underserved disease, and the people living with it deserve partners who listen as much as they invest," said Breck Jones, Jr., President, US WorldMeds. "We are honored by this recognition, and we share it with the patients, survivors, caregivers, and advocates who have shaped how we think about this work. Their voices have made our science more meaningful."

"US WorldMeds has distinguished itself in a remarkably short time through its significant contributions to the sarcoma community," said Brandi Felser, Chief Executive Officer, Sarcoma Foundation of America. "Their commitment to meaningfully including the patient voice reflects a forward-thinking approach that is both innovative and impactful."

What is TECELRA?

TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 2 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, fatigue, infection, fever (100.4°F/38°C or higher), constipation, vomiting, headache, diarrhea, fast heart rate, cough, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, decreased red blood cell count, and decreased platelet count.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to US WorldMeds at 1-855-246-9232.

Please see full Prescribing Information, including Boxed Warning and Medication Guide.

About US WorldMeds

US WorldMeds is a U.S.-based pharmaceutical company focused on rare and specialty treatments. Our portfolio includes approved therapies for rare diseases, including IWILFIN®, REVONTO®, and TECELRA.

Media Contact
Stephen Camiolo
Head of Cell Therapy Commercialization
USWM CT, LLC
Phone: 1-833-935-6676
Email: [email protected]

SOURCE US WorldMeds